{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T02:01:47Z","timestamp":1780020107415,"version":"3.53.1"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Zhejiang Provincial Natural Science Foundation of China","award":["LZ23E030003"],"award-info":[{"award-number":["LZ23E030003"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["21722405 and 22075243"],"award-info":[{"award-number":["21722405 and 22075243"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012602","name":"Startup Foundation for Hundred-Talent Program of Zhejiang University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012602","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-026-04185-9","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T03:04:43Z","timestamp":1776481483000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pre-existing anti-polyethylene glycol antibodies in pregnant women and newborns"],"prefix":"10.1186","volume":"24","author":[{"given":"Haiyang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changzheng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyang","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jicheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baohua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yisha","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meihua","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"key":"4185_CR1","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nrd1033","volume":"2","author":"JM Harris","year":"2003","unstructured":"Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003;2:214\u201321.","journal-title":"Nat Rev Drug Discov"},{"key":"4185_CR2","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3390\/polym12020298","volume":"12","author":"TTT Hoang","year":"2020","unstructured":"Hoang TTT, Pilkington EH, Nguyen DH, Lee JS, Park KD, Truong NP. The importance of poly(ethylene glycol) alternatives for overcoming PEG immunogenicity in drug delivery and bioconjugation. Polym (Basel). 2020;12:298.","journal-title":"Polym (Basel)"},{"key":"4185_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10600","volume":"9","author":"YS Gao","year":"2023","unstructured":"Gao YS, Joshi M, Zhao ZM, Mitragotri S. PEGylated therapeutics in the clinic. Bioeng Transl Med. 2023;9:e10600.","journal-title":"Bioeng Transl Med"},{"key":"4185_CR4","unstructured":"New Drug Therapy Approvals. 2025: U.S. Food and Drug Administration; 2025. https:\/\/www.fda.gov\/drugs\/novel-drug-approvals-fda\/novel-drug-approvals-2024. Accessed 26 Feb 2025."},{"key":"4185_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tox.2005.06.001","volume":"214","author":"C Fruijtier-P\u00f6lloth","year":"2005","unstructured":"Fruijtier-P\u00f6lloth C. Safety assessment on polyethylene glycols (PEGs) and their derivatives as used in cosmetic products. Toxicology. 2005;214:1\u201338.","journal-title":"Toxicology"},{"key":"4185_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.5487\/TR.2015.31.2.105","volume":"31","author":"H-J Jang","year":"2015","unstructured":"Jang H-J, Shin CY, Kim K-B. Safety evaluation of polyethylene glycol (PEG) compounds for cosmetic use. Toxicol Res. 2015;31:105\u201336.","journal-title":"Toxicol Res"},{"key":"4185_CR7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejpb.2020.04.026","volume":"152","author":"NE Elsadek","year":"2020","unstructured":"Elsadek NE, Abu Lila AS, Emam SE, Shimizu T, Takata H, Ando H, et al. Pegfilgrastim (PEG-G-CSF) induces anti-PEG IgM in a dose dependent manner and causes the accelerated blood clearance (ABC) phenomenon upon repeated administration in mice. Eur J Pharm Biopharm. 2020;152:56\u201362.","journal-title":"Eur J Pharm Biopharm"},{"key":"4185_CR8","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.jconrel.2021.08.051","volume":"338","author":"AM Talkington","year":"2021","unstructured":"Talkington AM, McSweeney MD, Zhang T, Li ZB, Nyborg AC, LaMoreaux B, et al. High MW polyethylene glycol prolongs circulation of pegloticase in mice with anti-PEG antibodies. J Control Release. 2021;338:804\u201312.","journal-title":"J Control Release"},{"key":"4185_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jconrel.2006.01.005","volume":"112","author":"T Ishida","year":"2006","unstructured":"Ishida T, Ichihara M, Wang X, Yamamoto K, Kimura J, Majima E, et al. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J Control Release. 2006;112:15\u201325.","journal-title":"J Control Release"},{"key":"4185_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jconrel.2021.05.001","volume":"334","author":"SE Emam","year":"2021","unstructured":"Emam SE, Elsadek NE, Abu Lila AS, Takata H, Kawaguchi Y, Shimizu T, et al. Anti-PEG IgM production and accelerated blood clearance phenomenon after the administration of PEGylated exosomes in mice. J Control Release. 2021;334:327\u201334.","journal-title":"J Control Release"},{"key":"4185_CR11","doi-asserted-by":"publisher","first-page":"R63","DOI":"10.1186\/ar4500","volume":"16","author":"MS Hershfield","year":"2014","unstructured":"Hershfield MS, Ganson NJ, Kelly SJ, Scarlett EL, Jaggers DA, Sundy JS. Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients. Arthritis Res Ther. 2014;16:R63.","journal-title":"Arthritis Res Ther"},{"key":"4185_CR12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110141","volume":"132","author":"YW Liu","year":"2018","unstructured":"Liu YW, Smith CA, Yang WJ, Thompson L, Dash A, Counts J, et al. Pegaspargase allergic reactions are related to anti-pegaspargase antibodies and to intensity of intrathecal therapy. Blood. 2018;132:2697.","journal-title":"Blood"},{"key":"4185_CR13","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/bjh.16254","volume":"189","author":"R Kloos","year":"2020","unstructured":"Kloos R, van der Sluis IM, Mastrobattista E, Hennink W, Pieters R, Verhoef JJ. Acute lymphoblastic leukaemia patients treated with PEGasparaginase develop antibodies to PEG and the succinate linker. Br J Haematol. 2020;189:442\u201351.","journal-title":"Br J Haematol"},{"key":"4185_CR14","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/art.22403","volume":"56","author":"JS Sundy","year":"2007","unstructured":"Sundy JS, Ganson NJ, Kelly SJ, Scarlett EL, Rehrig CD, Huang W, et al. Pharmacokinetics and pharmacodynamics of intravenous pegylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum. 2007;56:1021\u20138.","journal-title":"Arthritis Rheum"},{"key":"4185_CR15","doi-asserted-by":"publisher","first-page":"R12","DOI":"10.1186\/ar1861","volume":"8","author":"NJ Ganson","year":"2006","unstructured":"Ganson NJ, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous pegylated urate oxidase. Arthritis Res Ther. 2006;8:R12.","journal-title":"Arthritis Res Ther"},{"key":"4185_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ymgme.2018.03.006","volume":"124","author":"J Thomas","year":"2018","unstructured":"Thomas J, Levy H, Amato S, Vockley J, Zori R, Dimmock D, et al. Pegvaliase for the treatment of phenylketonuria: results of a long-term phase 3 clinical trial program (PRISM). Mol Genet Metab. 2018;124:27\u201338.","journal-title":"Mol Genet Metab"},{"key":"4185_CR17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/cncr.22739","volume":"110","author":"JK Armstrong","year":"2007","unstructured":"Armstrong JK, Hempel G, Koling S, Chan LS, Fisher T, Meiselman HJ, et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer. 2007;110:103\u201311.","journal-title":"Cancer"},{"key":"4185_CR18","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/wnan.1339","volume":"7","author":"Q Yang","year":"2015","unstructured":"Yang Q, Lai SK. Anti-PEG immunity: emergence, characteristics, and unaddressed questions. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015;7:655\u201377.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"4185_CR19","first-page":"36","volume":"74","author":"AW Richter","year":"1984","unstructured":"Richter AW, Akerblom E. Polyethylene-glycol reactive antibodies in man - titer distribution in allergic patients treated with monomethoxy polyethylene-glycol modified allergens or placebo, and in healthy blood-donors. Int Arch Allergy Appl Immunol. 1984;74:36\u20139.","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"4185_CR20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41577-022-00825-x","volume":"23","author":"Y Ju","year":"2023","unstructured":"Ju Y, Carreno JM, Simon V, Dawson K, Krammer F, Kent SJ. Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines. Nat Rev Immunol. 2023;23:135\u20136.","journal-title":"Nat Rev Immunol"},{"key":"4185_CR21","doi-asserted-by":"publisher","first-page":"14022","DOI":"10.1021\/acsnano.1c05922","volume":"15","author":"BM Chen","year":"2021","unstructured":"Chen BM, Cheng TL, Roffler SR. Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies. ACS Nano. 2021;15:14022\u201348.","journal-title":"ACS Nano"},{"key":"4185_CR22","doi-asserted-by":"publisher","first-page":"114079","DOI":"10.1016\/j.addr.2021.114079","volume":"180","author":"D Shi","year":"2022","unstructured":"Shi D, Beasock D, Fessler A, Szebeni J, Ljubimova JY, Afonin KA, et al. To pegylate or not to pegylate: immunological properties of nanomedicine\u2019s most popular component, polyethylene glycol and its alternatives. Adv Drug Deliv Rev. 2022;180:114079.","journal-title":"Adv Drug Deliv Rev"},{"key":"4185_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00766-z","volume":"8","author":"HY Wang","year":"2023","unstructured":"Wang HY, Wang YS, Yuan CZ, Xu X, Zhou WB, Huang YH, et al. Polyethylene glycol (PEG)-associated immune responses triggered by clinically relevant lipid nanoparticles in rats. NPJ Vaccines. 2023;8:169.","journal-title":"NPJ Vaccines"},{"key":"4185_CR24","doi-asserted-by":"publisher","first-page":"11769","DOI":"10.1021\/acsnano.2c04543","volume":"16","author":"Y Ju","year":"2022","unstructured":"Ju Y, Lee WS, Pilkington EH, Kelly HG, Li SY, Selva KJ, et al. Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine. ACS Nano. 2022;16:11769\u201380.","journal-title":"ACS Nano"},{"key":"4185_CR25","doi-asserted-by":"publisher","first-page":"27077","DOI":"10.1021\/acsnano.4c11652","volume":"18","author":"JK Stephen","year":"2024","unstructured":"Stephen JK, Shiyao L, Thakshila A, Arnold R, Wen Shi L, Michael GL, et al. Blood distribution of SARS-CoV-2 lipid nanoparticle mRNA vaccine in humans. ACS Nano. 2024;18:27077\u201389.","journal-title":"ACS Nano"},{"issue":"16","key":"4185_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23168838","volume":"23","author":"G Guerrini","year":"2022","unstructured":"Guerrini G, Gioria S, Sauer AV, Lucchesi S, Montagnani F, Pastore G, et al. Monitoring anti-PEG antibodies level upon repeated lipid nanoparticle-based COVID-19 vaccine administration. Int J Mol Sci. 2022;23(16):8838.","journal-title":"Int J Mol Sci"},{"key":"4185_CR27","doi-asserted-by":"publisher","first-page":"6114","DOI":"10.1016\/j.vaccine.2022.08.024","volume":"40","author":"C Juan Manuel","year":"2022","unstructured":"Juan Manuel C, Gagandeep S, Johnstone T, Komal S, Charles G, Hiromi M, et al. mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations. Vaccine. 2022;40:6114\u201324.","journal-title":"Vaccine"},{"key":"4185_CR28","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jconrel.2022.12.039","volume":"354","author":"B Yaelle","year":"2023","unstructured":"Yaelle B, Bing-Mae C, Guy G, Alon YH, Keren T, Steve RR, et al. Anti-PEG antibodies before and after a first dose of Comirnaty (mRNA-LNP-based SARS-CoV-2 vaccine). J Control Release. 2023;354:316\u201322.","journal-title":"J Control Release"},{"key":"4185_CR29","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1126\/science.371.6524.10","volume":"371","author":"J de Vrieze","year":"2021","unstructured":"de Vrieze J. COVID-19 Pfizer\u2019s vaccine raises allergy concerns. Science. 2021;371:10\u20131.","journal-title":"Science"},{"key":"4185_CR30","doi-asserted-by":"publisher","first-page":"10661","DOI":"10.1021\/acs.analchem.6b03109","volume":"88","author":"BM Chen","year":"2016","unstructured":"Chen BM, Su YC, Chang CJ, Burnouf PA, Chuang KH, Chen CH, et al. Measurement of pre-existing IgG and IgM antibodies against polyethylene glycol in healthy individuals. Anal Chem. 2016;88:10661\u20136.","journal-title":"Anal Chem"},{"key":"4185_CR31","doi-asserted-by":"publisher","first-page":"11804","DOI":"10.1021\/acs.analchem.6b03437","volume":"88","author":"Q Yang","year":"2016","unstructured":"Yang Q, Jacobs TM, McCallen JD, Moore DT, Huckaby JT, Edelstein JN, et al. Analysis of pre-existing IgG and IgM antibodies against plyethylene glycol (PEG) in the general population. Anal Chem. 2016;88:11804\u201312.","journal-title":"Anal Chem"},{"key":"4185_CR32","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1007\/s11095-016-1961-x","volume":"33","author":"C Lubich","year":"2016","unstructured":"Lubich C, Allacher P, de la Rosa M, Bauer A, Prenninger T, Horling FM, et al. The mystery of antibodies against polyethylene glycol (PEG) - what do we know? Pharm Res. 2016;33:2239\u201349.","journal-title":"Pharm Res"},{"key":"4185_CR33","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.toxrep.2020.12.022","volume":"8","author":"JL Fang","year":"2021","unstructured":"Fang JL, Beland FA, Tang YS, Roffler SR. Flow cytometry analysis of anti-polyethylene glycol antibodies in human plasma. Toxicol Rep. 2021;8:148\u201354.","journal-title":"Toxicol Rep"},{"key":"4185_CR34","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.jconrel.2024.01.003","volume":"366","author":"Z Li","year":"2024","unstructured":"Li Z, Ma A, Miller I, Starnes R, Talkington A, Stone CA, et al. Development of anti-PEG IgG\/IgM\/IgE ELISA assays for profiling anti-PEG immunoglobulin response in PEG-sensitized individuals and patients with alpha-gal allergy. J Control Release. 2024;366:342\u20138.","journal-title":"J Control Release"},{"key":"4185_CR35","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1039\/D3NH00198A","volume":"8","author":"MFS Deuker","year":"2023","unstructured":"Deuker MFS, Mail\u00e4nder V, Morsbach S, Landfester K. Anti-PEG antibodies enriched in the protein Corona of pegylated nanocarriers impact the cell uptake. Nanoscale Horiz. 2023;8:1377\u201385.","journal-title":"Nanoscale Horiz"},{"key":"4185_CR36","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nri.2017.64","volume":"17","author":"G Mor","year":"2017","unstructured":"Mor G, Aldo P, Alvero AB. The unique immunological and microbial aspects of pregnancy. Nat Rev Immunol. 2017;17:469\u201382.","journal-title":"Nat Rev Immunol"},{"key":"4185_CR37","doi-asserted-by":"publisher","first-page":"633","DOI":"10.3390\/polym13040633","volume":"13","author":"F Jummaat","year":"2021","unstructured":"Jummaat F, Yahya EB, Khalil AHPS, Adnan AS, Alqadhi AM, Abdullah CK, et al. The role of biopolymer-based materials in obstetrics and gynecology applications: a review. Polym (Basel). 2021;13:633.","journal-title":"Polym (Basel)"},{"key":"4185_CR38","volume":"5","author":"S Niewiesk","year":"2015","unstructured":"Niewiesk S. Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies. Front Immunol. 2015;5:446.","journal-title":"Front Immunol"},{"key":"4185_CR39","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/985646","volume":"2012","author":"P Palmeira","year":"2012","unstructured":"Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012;2012:985646.","journal-title":"Clin Dev Immunol"},{"key":"4185_CR40","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1016\/S0264-410X(03)00334-7","volume":"21","author":"NE Simister","year":"2003","unstructured":"Simister NE. Placental transport of immunoglobulin G. Vaccine. 2003;21:3365-9.","journal-title":"Vaccine"},{"key":"4185_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics3010001","volume":"3","author":"M Ichihara","year":"2010","unstructured":"Ichihara M, Shimizu T, Imoto A, Hashiguchi Y, Uehara Y, Ishida T, et al. Anti-PEG IgM response against PEGylated liposomes in mice and rats. Pharmaceutics. 2010;3:1-11.","journal-title":"Pharmaceutics"},{"key":"4185_CR42","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1093\/aje\/kwk052","volume":"165","author":"E Vittinghoff","year":"2017","unstructured":"Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2007;165:710-8.","journal-title":"Am J Epidemiol"},{"key":"4185_CR43","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","volume":"154","author":"GT Kozma","year":"2020","unstructured":"Kozma GT, Shimizu T, Ishida T, Szebeni J. Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. Adv Drug Deliv Rev. 2020;154:163-75.","journal-title":"Adv Drug Deliv Rev"},{"key":"4185_CR44","doi-asserted-by":"crossref","unstructured":"Gaballa SA, Shimizu T, Ando H, Takata H, Emam SE, Ramadan E, et al. Treatment-induced and pre-existing anti-peg antibodies: prevalence, clinical implications, and future perspectives. J Pharm Sci. 2024;113:555-78.","DOI":"10.1016\/j.xphs.2023.11.001"},{"key":"4185_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2024.102163","volume":"55","author":"JR Fu","year":"2024","unstructured":"Fu JR, Wu ER, Li GH, Wang B, Zhan CY. Anti-PEG antibodies: current situation and countermeasures. Nano Today. 2024;55: 102163.","journal-title":"Nano Today"},{"key":"4185_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00520","volume":"5","author":"G Vidarsson","year":"2014","unstructured":"Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520.","journal-title":"Front Immunol"},{"key":"4185_CR47","doi-asserted-by":"publisher","first-page":"14","DOI":"10.4049\/immunohorizons.1700057","volume":"2","author":"AG Cassidy","year":"2018","unstructured":"Fouda GG, Martinez DR, Swamy GK, Permar SR. The impact of IgG transplacental transfer on early life immunity. ImmunoHorizons. 2018;2:14-25.","journal-title":"ImmunoHorizons"},{"key":"4185_CR48","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.23405","volume":"6","author":"AG Cassidy","year":"2023","unstructured":"Cassidy AG, Li L, Golan Y, Gay C, Lin CY, Jigmeddagva U, et al. Assessment of adverse reactions, antibody patterns, and 12-month outcomes in the mother-infant Dyad after COVID-19 mRNA vaccination in pregnancy. JAMA Network Open. 2023;6:e2323405.","journal-title":"JAMA Network Open"},{"key":"4185_CR49","first-page":"35","volume":"54","author":"E Helena","year":"2014","unstructured":"Helena E, Johanna M, Zinnia PPG, Charlotte K. Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children. Clin pharmacokinet. 2014;54:35-80.","journal-title":"Clin pharmacokinet"},{"key":"4185_CR50","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/S0169-409X(03)00030-9","volume":"55","author":"A Jane","year":"2003","unstructured":"Jane A, Patrick JM. Pharmacokinetics in the newborn. Adv Drug Deliv Rev. 2003;55:667-686.","journal-title":"Adv Drug Deliv Rev"},{"key":"4185_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2020.101919","volume":"39","author":"RH Novoa","year":"2021","unstructured":"Novoa RH, Quintana W, Llancar\u00ed P, Urbina-Quispe K, Guevara-R\u00edos E, Ventura W. Maternal clinical characteristics and perinatal outcomes among pregnant women with coronavirus disease 2019. a systematic review. Travel Med Infect Dis. 2021;39:101919.","journal-title":"Travel Med Infect Dis"},{"key":"4185_CR52","first-page":"1848","volume":"323","author":"H Zeng","year":"2020","unstructured":"Zeng H, Xu C, Fan JL, Tang YT, Deng QL, Zhang W, et al. Antibodies in infants born to mothers with COVID-19 pneumonia. JAMA. 2020;323:1848-9.","journal-title":"JAMA"},{"key":"4185_CR53","first-page":"1788","volume":"323","author":"DW Kimberlin","year":"2020","unstructured":"Kimberlin DW, Stagno S. Can SARS-CoV-2 infection be acquired in utero? more definitive evidence is needed. JAMA. 2020;323:1788-9.","journal-title":"JAMA"},{"key":"4185_CR54","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s00281-017-0653-x","volume":"39","author":"MF Jennewein","year":"2017","unstructured":"Jennewein MF, Abu-Raya B, Jiang YW, Alter G, Marchant A. Transfer of maternal immunity and programming of the newborn immune system. Semin Immunopathol. 2017;39:605-13.","journal-title":"Semin Immunopathol"},{"key":"4185_CR55","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jconrel.2023.01.012","volume":"354","author":"M Ibrahim","year":"2023","unstructured":"Ibrahim M, Shimizu T, Ando H, Ishima Y, Elgarhy OH, Sarhan HA, et al. Investigation of anti-PEG antibody response to PEG-containing cosmetic products in mice. J Control Release. 2023;354:260-7.","journal-title":"J Control Release"},{"key":"4185_CR56","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1021\/acs.molpharmaceut.3c00774","volume":"21","author":"SA Gaballa","year":"2024","unstructured":"Gaballa SA, Ando H, Ibrahim M, Amorim Matsuo NC, Naguib YW, Mady FM, et al. Impact of anti-PEG IgM induced via the topical application of a cosmetic product containing PEG derivatives on the antitumor effects of PEGylated liposomal antitumor drug formulations in mice. Mol Pharm. 2024;21:622-32.","journal-title":"Mol Pharm"},{"key":"4185_CR57","doi-asserted-by":"publisher","first-page":"4561","DOI":"10.1016\/j.vaccine.2023.06.009","volume":"41","author":"GT Kozma","year":"2023","unstructured":"Kozma GT, M\u00e9sz\u00e1ros T, Ber\u00e9nyi P, Facsk\u00f3 R, Patk\u00f3 Z, Ol\u00e1h CZ, et al. Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: evidence for immunogenicity of PEG. Vaccine. 2023;41:4561-70.","journal-title":"Vaccine"},{"key":"4185_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2021.145997","volume":"777","author":"W Leal","year":"2021","unstructured":"Leal W, Voronova V, Kloga M, Pa\u00e7o A, Minhas A, Salvia AL, et al. COVID-19 and waste production in households: a trend analysis. Science Total Environ. 2021;777:145997.","journal-title":"Science Total Environ"},{"key":"4185_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.gfs.2022.100658","volume":"35","author":"XB Wang","year":"2022","unstructured":"Wang XB, Zhao FX, Tian X, Min S, von Cramon-Taubadel S, Huang JK, et al. How online food delivery platforms contributed to the resilience of the urban food system in China during the COVID-19 pandemic. Glob Food Secur. 2022;35:100658.","journal-title":"Glob Food Secur"},{"key":"4185_CR60","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jconrel.2007.02.010","volume":"119","author":"XY Wang","year":"2007","unstructured":"Wang XY, Ishida T, Kiwada H. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Control Release. 2007;119:236-44.","journal-title":"J Control Release"},{"key":"4185_CR61","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1002\/jps.23254","volume":"101","author":"CL Li","year":"2012","unstructured":"Li CL, Cao JN, Wang YJ, Zhao X, Deng CX, Wei N, et al. Accelerated blood clearance of pegylated liposomal topotecan: influence of polyethylene glycol grafting density and animal species. J Pharm Sci. 2012;101:3864-76.","journal-title":"J Pharm Sci"},{"key":"4185_CR62","doi-asserted-by":"publisher","first-page":"598","DOI":"10.3109\/10717544.2014.885998","volume":"22","author":"H Xu","year":"2015","unstructured":"Xu H, Ye FF, Hu MN, Yin PP, Zhang W, Li Y, et al. Influence of phospholipid types and animal models on the accelerated blood clearance phenomenon of PEGylated liposomes upon repeated injection. Drug Deliv. 2015;22:598-607.","journal-title":"Drug Deliv"},{"key":"4185_CR63","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.xphs.2018.10.027","volume":"108","author":"FL Wang","year":"2019","unstructured":"Wang FL, Ye X, Wu YF, Wang HH, Sheng CM, Peng DY, et al. Time interval of two injections and first-dose dependent of accelerated blood clearance phenomenon induced by PEGylated liposomal gambogenic acid: the contribution of PEG-specific IgM. J Pharm Sci. 2019;108:641-51.","journal-title":"J Pharm Sci"},{"key":"4185_CR64","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1021\/acs.molpharmaceut.5b00144","volume":"12","author":"Y Mima","year":"2015","unstructured":"Mima Y, Hashimoto Y, Shimizu T, Kiwada H, Ishida T. Anti-PEG IgM is a major contributor to the accelerated blood clearance of polyethylene glycol-conjugated protein. Mol Pharma. 2015;12:2429-35.","journal-title":"Mol Pharma"},{"key":"4185_CR65","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1021\/acs.molpharmaceut.0c00366","volume":"17","author":"NE Elsadek","year":"2020","unstructured":"Elsadek NE, Hondo E, Shimizu T, Takata H, Abu Lila AS, Emam SE, et al. Impact of pre-existing or induced anti-PEG IgM on the pharmacokinetics of peginterferon Alfa-2a (Pegasys) in mice. Mol Pharma. 2020;17:2964-70.","journal-title":"Mol Pharma"},{"key":"4185_CR66","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1007\/s11095-009-9943-x","volume":"26","author":"T Ishihara","year":"2009","unstructured":"Ishihara T, Takeda M, Sakamoto H, Kimoto A, Kobayashi C, Takasaki N, et al. Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles. Pharm Res. 2009;26:2270-9.","journal-title":"Pharm Res"},{"key":"4185_CR67","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ijpharm.2012.04.049","volume":"432","author":"H Koide","year":"2012","unstructured":"Koide H, Asai T, Kato H, Ando H, Shiraishi K, Yokoyama M, et al. Size-dependent induction of accelerated blood clearance phenomenon by repeated injections of polymeric micelles. Int J Pharma. 2012;432:75-9.","journal-title":"Int J Pharma"},{"key":"4185_CR68","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.ultrasmedbio.2018.02.006","volume":"44","author":"SM Fix","year":"2018","unstructured":"Fix SM, Nyankima AG, McSweeney MD, Tsuruta JK, Lai SK, Dayton PA. Accelerated clearance of ultrasound contrast agents containing polyethylene glycol is associated with the generation of anti- polyethylene glycol antibodies. Ultrasound Med Biol. 2018;44:1266-80.","journal-title":"Ultrasound Med Biol"},{"key":"4185_CR69","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jconrel.2021.12.033","volume":"342","author":"C Stavnsbjerg","year":"2022","unstructured":"Stavnsbjerg C, Christensen E, M\u00fcnter R, Henriksen JR, Fach M, Parhamifar L, et al. Accelerated blood clearance and hypersensitivity by PEGylated liposomes containing TLR agonists. J Control Release. 2022;342:337-44.","journal-title":"J Control Release"},{"key":"4185_CR70","doi-asserted-by":"publisher","first-page":"9315","DOI":"10.1021\/acsnano.9b03942","volume":"13","author":"GT Kozma","year":"2019","unstructured":"Kozma GT, M\u00e9sz\u00e1ros T, Vashegyi I, F\u00fcl\u00f6p T, \u00d6rfi E, D\u00e9zsi L, et al. Pseudo-anaphylaxis to polyethylene glycol (PEG)-coated liposomes: roles of anti-PEG IgM and complement activation in a porcine model of human infusion reactions. ACS Nano. 2019;13:9315-24.","journal-title":"ACS Nano"},{"key":"4185_CR71","doi-asserted-by":"publisher","first-page":"5757","DOI":"10.1021\/acsnano.2c12193","volume":"17","author":"WA Chen","year":"2023","unstructured":"Chen WA, Chang DY, Chen BM, Lin YC, Barenholz Y, Roffler SR. Antibodies against poly(ethylene glycol) activate innate immune cells and induce hypersensitivity reactions to PEGylated nanomedicines. ACS Nano. 2023;17:5757-72.","journal-title":"ACS Nano"},{"key":"4185_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/ar4497","volume":"16","author":"PE Lipsky","year":"2014","unstructured":"Lipsky PE, Calabrese LH, Kavanaugh A, Sundy JS, Wright D, Wolfson M, et al. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014;16:R60.","journal-title":"Arthritis Res Ther"},{"key":"4185_CR73","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3324\/haematol.2020.258525","volume":"107","author":"A Khalil","year":"2022","unstructured":"Khalil A, W\u00fcrthwein G, Golitsch J, Hempel G, Fobker M, Gerss J, et al. Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated asparaginase in children with acute lymphocytic leukemia. Haematologica. 2022;107:49-57.","journal-title":"Haematologica"},{"key":"4185_CR74","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/j.jaci.2015.10.034","volume":"137","author":"NJ Ganson","year":"2016","unstructured":"Ganson NJ, Povsic TJ, Sullenger BA, Alexander JH, Zelenkofske SL, Sailstad JM, et al. Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer. J Allergy Clin Immun. 2016;137:1610-3.","journal-title":"J Allergy Clin Immun"},{"key":"4185_CR75","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1208\/s12248-012-9408-8","volume":"15","author":"L Zhou","year":"2013","unstructured":"Zhou L, Hoofring SA, Wu Y, Vu T, Ma PM, Swanson SJ, et al. Stratification of antibody-positive subjects by antibody level reveals an impact of immunogenicity on pharmacokinetics. AAPS J. 2013;15:30-40.","journal-title":"AAPS J"},{"key":"4185_CR76","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1128\/CVI.00131-10","volume":"17","author":"SA Plotkin","year":"2010","unstructured":"Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17:1055-65.","journal-title":"Clin Vaccine Immunol"},{"key":"4185_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100334","volume":"21","author":"M Zahreddine","year":"2020","unstructured":"Zahreddine M, Mayrand MH, Therrien C, Trevisan A, Monnier P, Laporte L, et al. Antibodies to human papillomavirus types 6, 11, 16 and 18: vertical transmission and clearance in children up to two years of age. Eclinicalmedicine. 2020;21:100334.","journal-title":"Eclinicalmedicine"},{"key":"4185_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100412","volume":"2","author":"AS Thomas","year":"2021","unstructured":"Thomas AS, Isaac JE, White LF, Kourtis AP, Moreau Y, Jiang W, et al. Pre-existing infant antibody-dependent cellular cytotoxicity associates with reduced HIV-1 acquisition and lower morbidity. Cell Rep Med. 2021;2:100412.","journal-title":"Cell Rep Med"},{"key":"4185_CR79","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1093\/infdis\/jiab513","volume":"225","author":"CJ Forsyth","year":"2022","unstructured":"Forsyth CJ, Bern C, Whitman J, Castro Y, Coyle C, Gilman R, et al. Recommendations for screening and diagnosis of chagas disease in the united states. J Infect Dis. 2022;225:1601-10.","journal-title":"J Infect Dis"},{"key":"4185_CR80","doi-asserted-by":"crossref","unstructured":"Gao X, Yan XY, Wang RY, Li C, Qiu QJ, Liu MY, et al. Discovery in polyethylene glycol immunogenecity: the characteristic of intergenerational inheritance of anti-polyethylene glycol IgG. Eur J Pharm Biopharm. 2022;172;89-100.","DOI":"10.1016\/j.ejpb.2022.01.008"},{"key":"4185_CR81","unstructured":"Coronavirus (COVID-19) update: FDA authorizes Moderna and Pfizer-BioNTech COVID-19 vaccines for children down to 6 months of age: U.S. Food and Drug Administration. 2022 https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-moderna-and-pfizer-biontech-covid-19-vaccines-children. Accessed 22 June 2022."},{"key":"4185_CR82","unstructured":"FDA approves calaspargase pegol-mknl for young patients with ALL: Parmacy Times. 2018. https:\/\/www.pharmacytimes.com\/view\/fda-approves-calaspargase-pegolmknl-for-young-patients-with-all. Accessed 21 Dec 2018."},{"key":"4185_CR83","unstructured":"Neulasta\u00ae prescribing information: Amgen. 2025. https:\/\/www.pi.amgen.com\/-\/media\/Project\/Amgen\/Repository\/pi-amgen-com\/Neulasta\/neulasta_pi_hcp_english.pdf. Accessed Aug 2025."},{"key":"4185_CR84","unstructured":"Revcovi\u00ae:. Drugs.com; 2024. https:\/\/www.drugs.com\/mtm\/revcovi.html. Accessed 31 Dec 2024."},{"key":"4185_CR85","doi-asserted-by":"crossref","unstructured":"Food Drug A, Cder, Cber. Guidance for industry: immunogenicity assessment for therapeutic protein products. Biotechnol Law Rep. 2013;32:172-85.","DOI":"10.1089\/blr.2013.9927"},{"key":"4185_CR86","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/EDE.0b013e3181577654","volume":"18","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement guidelines for reporting observational studies. Epidemiology. 2007;18:800-4.","journal-title":"Epidemiology"},{"key":"4185_CR87","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2196\/jmir.6.3.e34","volume":"6","author":"G Eysenbach","year":"2004","unstructured":"Eysenbach G. Improving the quality of web surveys: the checklist for reporting results of internet e-surveys (CHERRIES). J Med Internet Res. 2004;6:12-6.","journal-title":"J Med Internet Res"},{"key":"4185_CR88","doi-asserted-by":"crossref","unstructured":"Burns KEA, Duffett M, Kho ME, Meade MO, Adhikari NKJ, Sinuff T, et al. A guide for the design and conduct of self-administered surveys of clinicians. Can Med Assoc J. 2008;179:245\u201352.","DOI":"10.1503\/cmaj.080372"},{"key":"4185_CR89","unstructured":"Safety assessment of PEG diesters as used in cosmetics: Cosmetic Ingredient Review (CIR) Expert Panel; 2014. https:\/\/www.cir-safety.org\/sites\/default\/files\/peg_diesters.pdf?utm_source=chatgpt.com. Accessed 14 Nov 2014."}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04185-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04185-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04185-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T01:02:01Z","timestamp":1780016521000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-04185-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,18]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4185"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04185-9","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,18]]},"assertion":[{"value":"13 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Women\u2019s Hospital, Zhejiang University School of Medicine (approval No. IRB-20210139-R) and carefully followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. All participants provided informed consent to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agree to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"512"}}